Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gynecologic malignancies.

R C Young

    Cancer Chemotherapy and Biological Response Modifiers
    |January 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Combination chemotherapy shows promise in ovarian cancer treatment, offering higher response rates. Alkylating agent maintenance and total abdominal radiation therapy are not recommended due to complications and limited benefits, respectively.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The sounds of silence.

    Nature·2000
    Same author

    Cervical epidermal growth factor-receptor (EGF-R) and serum insulin-like growth factor II (IGF-II) levels are potential markers for cervical cancer.

    American journal of reproductive immunology (New York, N.Y. : 1989)·2000
    Same author

    Automated oxyhemoglobin dissociation curve construction to assess sickle cell anemia therapy.

    Journal of the National Medical Association·2000
    Same author

    Up-regulation of epidermal growth factor-receptors (EGF-R) by nicotine in cervical cancer cell lines: this effect may be mediated by EGF.

    American journal of reproductive immunology (New York, N.Y. : 1989)·2000
    Same author

    Fox Chase Network: Fox Chase Cancer Center's community hospital affiliation program.

    The oncologist·2000
    Same author

    Three cycles versus six cycles of adjuvant paclitaxel (Taxol)/carboplatin in early stage ovarian cancer.

    Seminars in oncology·2000
    Same journal

    Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    DNA vaccines for melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Chemotherapy, cytokines, and biochemotherapy for melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Current status of interferon-alpha in the treatment of melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    See all related articles

    Area of Science:

    • Gynecologic Oncology
    • Medical Oncology
    • Clinical Trials

    Background:

    • Prospective trials are evaluating current treatment strategies for ovarian, cervical, and endometrial cancers.
    • Combination chemotherapy generally yields higher response rates than single agents in ovarian cancer.

    Purpose of the Study:

    • To summarize emerging conclusions from prospective trials in gynecologic cancer treatment.
    • To assess the efficacy and toxicity of various chemotherapy regimens and radiation therapy approaches.

    Main Methods:

    • Review of prospective clinical trials in ovarian, cervical, and endometrial cancer.
    • Analysis of response rates, remission rates, survival data, and treatment-related complications.

    Main Results:

    Related Experiment Videos

    • Combination chemotherapy demonstrates superior response and remission rates in ovarian cancer compared to single agents.
    • Alkylating agent maintenance and total abdominal radiation therapy post-chemotherapy show limited benefit and significant toxicity (leukemia).
    • Salvage chemotherapy has been largely unsatisfactory, with some promise for low-dose mitomycin C and VP-16/cisplatin combinations.
    • Carboplatin and ifosfamide show activity in cervical cancer but have side effects; radiation sensitizers and low-dose cisplatin are under investigation.
    • Estrogen use and endometrial cancer risk are being further defined; combination chemotherapy shows activity in endometrial cancer.

    Conclusions:

    • Combination chemotherapy is preferred for ovarian cancer, but alkylating agent maintenance and total abdominal radiation should be avoided.
    • Further research is needed for cervical and endometrial cancers, particularly regarding new drug combinations and radiation sensitizers.
    • Salvage chemotherapy options require further investigation.